JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Tel: +1-832-696-8203
Email: [email protected]
Worldwide Distributors
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Cell lines
Vascular smooth muscle cells (VSMCs)
Reaction Conditions
0, 1, 5, 10 μM losartan for 48 h incubation
Applications
Losartan dose-dependently decreased the angiotensin Ⅱ (Ang Ⅱ)- or 15% fetal bovine serum (FBS)-induced VSMC proliferation by inhibiting the expression of cell cycle associated proteins, such as p-Rb, cyclin D, and cyclin E.
Animal models
Wistar-Kyoto (WKY) rats and stroke-prone, spontaneously hypertensive rats (SHR-SP)
Dosage form
10 mg/kg/day
Administered by oral route for 2 weeks
In SHR-SP, losartan decreased systolic blood pressure, increased the number of circulating endothelial progenitor cells (EPCs) and colony formation, and inhibited oxidation. In addition, losartan was able to stimulated EPC migration. These data suggest that losartan can improve the proliferation and function of EPCs in hypertension, with the potential to repair hypertensive vascular injuries.
Note
The technical data provided above is for reference only.
References:
1. Kim JE, Choi HC. Losartan inhibits vascular smooth muscle cell proliferation through activation of AMP-activated protein kinase. The Korean Journal of Physiology & Pharmacology, 2010, 14(5): 299-304.
2. Yao EH, Fukuda N, Matsumoto T, et al. Losartan improves the impaired function of endothelial progenitor cells in hypertension via an antioxidant effect. Hypertension Research, 2007, 30(11): 1119-1128.